A Phase 1 Study to Evaluate the Pharmacokinetic and Pharmacodynamic Profile, Safety, and Tolerability of Escalating Single Dose Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2014
Price : $35 *
At a glance
- Drugs Albumin interferon alpha 2A fusion protein (Primary) ; Peginterferon alfa-2a
- Indications Viral infections
- Focus Adverse reactions
- Sponsors Beijing Bio-Fortune
- 16 Nov 2014 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 20 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 27 Jul 2013 New trial record